Kyle L. Flannigan

机构：Boehringer Ingelheim (Brazil), Boehringer Ingelheim (France) · ORCID：0000-0002-9449-8879

发表论文 70 篇 · 总被引 2176 次 · h-index 24

代表论文

• Vancomycin relieves mycophenolate mofetil–induced gastrointestinal toxicity by eliminating gut bacterial β-glucuronidase activity (2019 · Science Advances · 被引 124)
• The Pregnane X Receptor and Indole-3-Propionic Acid Shape the Intestinal Mesenchyme to Restrain Inflammation and Fibrosis (2022 · Cellular and Molecular Gastroenterology and Hepatology · 被引 89)
• Targeting the pregnane X receptor using microbial metabolite mimicry (2020 · EMBO Molecular Medicine · 被引 82)
• Pregnane X Receptor Activation Triggers Rapid ATP Release in Primed Macrophages That Mediates NLRP3 Inflammasome Activation (2019 · Journal of Pharmacology and Experimental Therapeutics · 被引 36)
• Xenobiotic receptors and the regulation of intestinal homeostasis: harnessing the chemical output of the intestinal microbiota (2021 · American Journal of Physiology-Gastrointestinal and Liver Physiology · 被引 31)
• The xenobiotic sensing pregnane X receptor regulates tissue damage and inflammation triggered by C difficile toxins (2019 · The FASEB Journal · 被引 19)